1Nusslein-Volhard C,Wieschaus E,Kluding H.Mutations affecting the patern of the larval cuticle in Drosophila melanogaster.I.Zygotic loci on the second chromosome.Wilhelm Roux′s Arch[J].Dev Biol,1984,193(9):267
2Song H,Ming G,He Z,et al.Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides[J].Science,1998,281(213):1515
3Rothberg JM,Jacobs JR,Goodman CS,et al.Slit:an extracellular protein necessary for CNS axon pathway formation contains both EGF and LRR domains[J].Genes Dev,1990,4(5):2169
4Kidd T,Brose K,Mitchell KJ,et al.Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors[J].Cell,1998,92(610):205
5Wang B,Xiao Y,Ding BB,et al.Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity[J].Cancer Cell,2003,4(137):19
6Latil A,Chene L,Cochant-Priollet B,et al.Quantification of expression of netrins,slits and their receptors in human prostate tumors[J].Int J Cancer,2003,103(97):306
7Dallol A,da Silva NF,Viacava P,et al.Slit2,a human homologue of the Drosophila Slit2 gene,has tumor suppressor activity and is frequently inactivated in lung and breast cancers[J].Cancer Res,2002,62(79):5874
8Dallol A,Krex D,Hesson L,et al.Frequent epigenetic inactivation of the Slit2 gene in gliomas[J].Oncogene,2003,22(94):4611
9Dallol A,Morton D,Maher ER,et al.Slit2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells[J].Cancer Res,2003,63(348):1054
10Austuti D,NF da Silva,Dallol A,et al.Slit2 promoter methylation analysis in neuroblastoma,Wilms' tumour and renal cell carcinoma[J].Br J Cancer,2004,90(106):515
二级参考文献26
1Barinaga M . Designing therapies that target tumor blood vessels[J].Science,1997,275:482.
2Augustin HG. Antiangiogenic tumour therapy: will it work [J].Trends Pharmacol Sci,1998,19:216.
3Dvorak H F. Tumors: wound that do not heal. Similarities between tumor srtoma generation and wound healing[J]. N Engl J Med, 1986, 315:1650.
4Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma[J]. Cancer Res, 1996,56:3004.
5Inoue K, Ozeki Y, Suganuma T, et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression[J]. Cancer, 1997,79(2):206.
6Kumatr R, Yoneda J, Bucana CD, et al. Regulation of dictinct steps of angiogenesis by different angiogenic molecules[J]. Int J Oncol, 1998, 12(4):749.
7Seandel M, Noack-Kunnmann K, Zhu D, et al. Growth factor induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen[J]. Blood, 2001, 97(8):2323.
8Peters KG, Coogan A, Berry D, et al. Expression of Tie2/Tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis[J]. Br J Cancer, 1998,77:51.
9Lin P, Poiven P, Dewhirst M, et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathological vascular growth[J].J Clin Invest, 1997,100:2072.
10Siegfried JM,Weissfeld LA,Luketich JD,et al.The clinical significance of hepatocyte growth factor for non-small cell lung cancer[J]. Ann Thorac Surg,1998,66(6):1915.
